Internal Medicine, Endocrinology, Diabetes, & Metabolism · Prosper, TX
NPI
1265760771
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2120 Prairie Dr Ste 301
Prosper, TX, 75078
Phone (214) 216-1359
Groups this clinician bills Medicare through
Medicare paid, 2024
$90K
1,647 services
Medicare patients, 2024
388
Average age 72
Drug cost, 2024
$2.3M
4,214 prescriptions
Company payments, 2025
$508
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sindhu B Igala was code 99214 (office e&m - established), 579 times for 299 patients. In total Sindhu B Igala billed 1,647 services in 19 codes, and Medicare paid $90K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 579 | 299 | $87.64 | $51K |
| 82947 Clinical Chemistry | Office | 270 | 154 | $3.82 | $1,032 |
| 95251 Test - Miscellaneous | Office | 203 | 98 | $23.84 | $4,840 |
| 99213 Office E&M - Established | Office | 110 | 88 | $57.74 | $6,351 |
| 76536 Ultrasound - Nonspecific | Office | 95 | 85 | $75.39 | $7,162 |
| 99204 Office E&M - New | Office | 76 | 76 | $116.37 | $8,844 |
| 99203 Office E&M - New | Office | 19 | 19 | $77.85 | $1,479 |
| 95923 Electrical Nerve Conductivity | Office | 18 | 17 | $79.67 | $1,434 |
| 10005 Other Organ Systems | Office | 14 | 14 | $97.47 | $1,365 |
By year: 2022 $105K for 2,033 services; 2023 $104K for 2,008 services; 2024 $90K for 1,647 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82947 Clinical Chemistry | 270 | 154 | $3.82 | $1,032 |
Medicare prescription drug claims, 2024
In 2024, the drug Sindhu B Igala prescribed most often to Medicare patients was Ozempic (Semaglutide), with 394 prescriptions and refills. In total Sindhu B Igala wrote 4,214 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 394 | 720 | 108 | $667K |
| Levothyroxine Sodium Generic | 382 | 1,015 | 116 | $3,613 |
| Humulin R U-500 Kwikpen Insulin Regular, Human | 149 | 244 | 35 | $225K |
| Metformin Hcl Generic | 139 | 382 | 52 | $723 |
| Tresiba Flextouch U-200 Insulin Degludec | 134 | 337 | 50 | $131K |
| Methimazole Generic | 118 | 297 | 38 | $1,127 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 115 | 255 | 54 | $13K |
| Mounjaro Tirzepatide | 111 | 181 | 32 | $192K |
| Atorvastatin Calcium Generic | 102 | 271 | 34 | $893 |
| Novolog Flexpen Insulin Aspart | 102 | 220 | 38 | $29K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 101 | 249 | 38 | $15K |
| Glimepiride Generic | 100 | 273 | 34 | $738 |
| Metformin Hcl Er Metformin Hcl | 79 | 226 | 25 | $317 |
| Humalog Kwikpen U-100 Insulin Lispro | 79 | 202 | 39 | $26K |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 64 | 118 | 21 | $18K |
Brand drugs: 2,334 claims; generic drugs: 1,510 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sindhu B Igala $508 ($508 in general payments such as food, travel and fees) from 12 companies. The largest payer was Amgen Inc. with $149.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 6 | $149 |
| Mannkind Corporation MNKD | 6 | $121 |
| Corcept Therapeutics CORT | 2 | $38.51 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $36.39 |
| Novo Nordisk Inc NVO | 2 | $35.95 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $24.32 |
| Ascensia Diabetes Care Us Inc. | 1 | $18.87 |
| IBSA Pharma Inc. | 1 | $18.42 |
| Xeris Pharmaceuticals, Inc. | 1 | $17.7 |
| Tandem Diabetes Care, Inc. TNDM | 1 | $16.41 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.